Bipolar Androgen Therapy in the management of prostate cancer

2021 ◽  
Vol 11 (9) ◽  
pp. 484-490
Author(s):  
Sylwiusz Niedobylski ◽  
Katarzyna Laszczak ◽  
Konrad Warchoł ◽  
Sara Moqbil ◽  
Karolina Kalicka
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Therapeutic Strategy ◽  
Hormone Resistance ◽  
Castration Resistance ◽  
High Cardiovascular Risk ◽  
Androgen Therapy ◽  
General Quality ◽  
Main Strategy

Introduction and purpose: Prostate cancer (PCa) as one of the most frequent neoplasms in men remains a challenge for oncologists. The main strategy of its treatment is the Androgen Deprivation Therapy (ADT) the principle of which is an inducement of hypogonadism. The lack of testosterone is not only a factor greatly contributing to a decrease of quality of life overall, but additionally it increases the odds of the complications, including low libido and erectile disfunction, metabolic abnormalities, high cardiovascular risk, osteoporosis, anaemia, or depression. ADT also has the potential of inducement of castration resistance (CRPC), which significantly worsen patients prognosis. The main purpose of this review is to explore the Bipolar Androgen Therapy (BAT), which has the potential to solve the aforementioned problems. State of knowledge: The mechanism of BAT action has been described. BAT is effective not only against CRPC, but androgen-dependant PCa as well. BAT reverses the hormone resistance in CRPC, thus allowing the rechallenging of the ADT. It has the direct cytotoxic effect on cancer cells. Additionally BAT increases the exponents of the general quality of life of the patients. There is a number of active clinical trials regarding BAT. Conclusions: BAT is a safe therapeutic strategy with the high efficacy in reversing hormone resistance in CRPC patients, thus significantly increasing their health prognoses and it allows to alleviate or avoid the adverse effects of ADT.

Predictors of General Quality of Life in Patients With Benign Prostate Hyperplasia or Prostate Cancer

1997 ◽  
Vol 157 (2) ◽  
pp. 534-538 ◽  
Author(s):  
Arnon Krongrad ◽  
Lisa J. Granville ◽  
Michael A. Burke ◽  
Richard M. Golden ◽  
Shenghan Lai ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Benign Prostate Hyperplasia ◽  
Prostate Hyperplasia ◽  
General Quality ◽  
Benign Prostate

Predictors of General Quality of Life in Patients With Benign Prostate Hyperplasia or Prostate Cancer

1997 ◽  
pp. 534-538 ◽  
Author(s):  
Arnon Krongrad ◽  
Lisa J. Granville ◽  
Michael A. Burke ◽  
Richard M. Golden ◽  
Shenghan Lai ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Benign Prostate Hyperplasia ◽  
Prostate Hyperplasia ◽  
General Quality ◽  
Benign Prostate

The association between statin use and outcomes in patients initiating androgen deprivation therapy.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 145-145 ◽  
Author(s):  
Robert James Hamilton ◽  
Keyue Ding ◽  
Juanita M. Crook ◽  
Christopher J. O'Callaghan ◽  
Celestia S. Higano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Statistical Significance ◽  
Prospective Trial ◽  
Androgen Deprivation ◽  
Castration Resistance ◽  
Cancer Specific Survival ◽  
Statin Use

145 Background: Studies are conflicting regarding the association between statin use and biochemical recurrence after surgery or radiotherapy for localized prostate cancer. A handful of studies have observed favorable associations between statins and prostate cancer-specific (PCSM) and overall mortality (OS), however, this has not been studied in an advanced disease cohort nor has the combination of statins and androgen deprivation therapy (ADT) been specifically studied. Methods: Patients with PSA >3 ng/mL after >1 year following primary or salvage radiotherapy (RT) were enrolled in a randomized trial of intermittent (IAD) vs. continuous (CAD) ADT (NCT00003653). Statin use at baseline and during the study was captured and modeled as a time-dependent covariate. The primary end-point was OS. Models were adjusted for age, time from RT to ADT and PSA at baseline. As results were nearly identical between the IAD and CAD arms they are reported as aggregates unless otherwise indicated. Results: Of 1,364 patients enrolled, 585 (43%) reported statin use during the study. Statin users were younger (72.7 vs. 73.8, p=0.001) and less likely to have PSA >15 (20 vs. 25%, p=0.04). Median follow-up was 6.9 years and 524 deaths occurred. Statin use was associated with a reduced risk of overall death (HR: 0.64; 95% C.I. 0.53 – 0.78, p<0.001) and PCSM (HR: 0.64, 95% C.I. 0.48 – 0.86, p=0.003). Statin users had 14% longer time to castration resistance but this did not reach statistical significance (p=0.15). In the IAD arm, statin users had more off-treatment intervals (p=0.04) and longer time off-treatment (median: 0.85 vs. 0.64 years, p=0.06). Across 6 functional domains, statin users reported better quality of life scores. Conclusions: In men treated with ADT following primary or salvage RT, statin use was associated with improved overall and prostate cancer-specific survival and improved quality of life. In patients treated with IAD, statin use was associated with more off-treatment intervals and longer time off-treatment. A prospective trial of statins in men commencing ADT is warranted to confirm this observation.

scholarly journals The Association of Long-term Treatment-related Side Effects With Cancer-specific and General Quality of Life Among Prostate Cancer Survivors

Urology ◽  
2014 ◽  
Vol 84 (2) ◽  
pp. 300-306 ◽  
Author(s):  
Kimberly M. Davis ◽  
Scott P. Kelly ◽  
George Luta ◽  
Catherine Tomko ◽  
Anthony B. Miller ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Side Effects ◽  
Cancer Survivors ◽  
Term Treatment ◽  
Prostate Cancer Survivors ◽  
Long Term Treatment ◽  
General Quality

386: Health Related Quality of Life in Low-Income, Uninsured Men with Prostate Cancer

2004 ◽  
Vol 171 (4S) ◽  
pp. 101-102
Author(s):  
Tracey L. Krupski ◽  
Arlene Fink ◽  
Lorna Kwan ◽  
Sarah Connor ◽  
Sally L. Maliski ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Low Income ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Psychological and Cognitive Aspects of Borderline Intellectual Functioning

2017 ◽  
Vol 22 (3) ◽  
pp. 159-166 ◽  
Author(s):  
Bastianina Contena ◽  
Stefano Taddei
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Intellectual Functioning ◽  
Clinical Impact ◽  
Review Of The Literature ◽  
Borderline Intellectual Functioning ◽  
General Quality ◽  
Meta Analyses ◽  
Over Time

Abstract. Borderline Intellectual Functioning (BIF) refers to a global IQ ranging from 71 to 84, and it represents a condition of clinical attention for its association with other disorders and its influence on the outcomes of treatments and, in general, quality of life and adaptation. Furthermore, its definition has changed over time causing a relevant clinical impact. For this reason, a systematic review of the literature on this topic can promote an understanding of what has been studied, and can differentiate what is currently attributable to BIF from that which cannot be associated with this kind of intellectual functioning. Using Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) criteria, we have conducted a review of the literature about BIF. The results suggest that this condition is still associated with mental retardation, and only a few studies have focused specifically on this condition.

Sign in / Sign up

Export Citation Format

Share Document